Intermediate for Carfilzomib. Carfilzomib (trade name: Kyprolis) is an anti-cancer drug acting as a selective proteasome inhibitor. Carfilzomib has been approved by the U.S Food and Drug Administration on July 20, 2012.
Product Name: (S)-tert-Butyl 1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-2-ylcarbamate
CAS Number: 87694-50-6
Molecular Weight:  274.3594
Molecular Formula:  C13H26N2O4
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.